Core Viewpoint - The approval of the new drug, Weishiping, by the National Medical Products Administration of China marks a significant milestone for the company, aimed at treating moderate to severe active ulcerative colitis in adults who have inadequate response to traditional therapies or biologics [1] Group 1: Drug Approval and Clinical Trials - The approval is based on the results of the ENLIGHTUC study, a multicenter Phase III clinical trial in Asia involving 340 patients, which demonstrated statistical significance and good safety profiles for Weishiping [1] - The global Phase III study, ELEVATEUC, also contributed to the approval process, indicating robust clinical evidence supporting the drug's efficacy [1] Group 2: Commercialization and Strategic Goals - The company plans to actively prepare for the commercialization of Weishiping, aiming to make the therapy available to domestic patients as soon as possible and to push for its inclusion in the national medical insurance catalog [1] - This approval is a key component of the company's 2030 development strategy, which emphasizes a dual approach of "BD cooperation + self-research" to achieve both commercialization and research value [1] - The company targets to exceed 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with an expected compound annual growth rate of over 50% from 2025 to 2030 [1]
云顶新耀新药维适平在华获批，2030年战略瞄准150亿元收入